Skip to main content
. Author manuscript; available in PMC: 2018 Jan 12.
Published in final edited form as: Transplantation. 2014 May 15;97(9):881–889. doi: 10.1097/TP.0000000000000024

TABLE 3.

Clinical characteristics of published transplant recipients with donor-derived WNV infection

Characteristic (No. of recipients with data)
No. of transplant recipients 20
Age (14)
 Mean (range), yr 52 (25–73)
 Median (range), yr 52 (25–73)
Sex (20)
 Male 10
 Female 4
 Not reported 6
Type of transplant (20)
 Kidney 9
 Liver 6
 Lung 3
 Heart 2
Immunosuppresive agents (13)
 Tacrolimus 12
 Corticosteroids 11
 Mycophenolate 10
 Antilymphocyte antibodies 7
 Cyclosporine 1
 Sirolimus 1
Days from transplant to symptoms (15)
 Mean (range), d 14 (5–37)
 Median (range), d 13 (5–37)
Clinical WNV diagnosis (20)
 Encephalitis 14
 WNV fever 1
 Asymptomatic 5
Initial symptoms (15)
 Fever, constitutional symptoms 10
 Fever, dyspnea 1
 Fever, altered mental status 1
 Altered mental status 1
 Encephalopathy 2
 Seizures 1
Neurological symptoms in patients with WNV encephalitis (11)
 Altered mental status 11
 Dysarthria 4
 Lower extremity weakness 4
 Flaccid paralysis 5
 Hemiparesis 2
 Facial nerve palsy 1
 Seizures 4
 Coma 8
WNV testing of serum
 Positive serum PCR 10/12a
 Positive serum IgM 15/18
 Positive serum IgG 5/8
 Positive tissue PCR (brain) 2/2
a

No. of transplant recipients positive/no. of transplant recipients tested.

WNV, West Nile virus; PCR, polymerase chain reaction.